Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Am J Gastroenterol. 2010 Mar;105(3):557-64. doi: 10.1038/ajg.2009.644. Epub 2009 Nov 10.
The association of interleukin-1B (IL-1B)-511 polymorphism with gastric cancer is still controversial, and the association of IL-1B-511 polymorphism with subtypes of gastric cancer is still largely unknown. We investigated whether the association between IL-1B-511 polymorphism and gastric cancer risk varies by clinically important tumor characteristics and the prognostic value of this polymorphism in a large population-based case-control study among Chinese.
A population-based case-control study was conducted between 1999 and 2006 in Guangdong Province, China. A total of 1,010 gastric cancer patients and 1,500 healthy controls were enrolled in this study. Polymorphism in IL-1B-511 was analyzed by PCR-restriction fragment length polymorphism on 501 gastric cancers and 500 healthy controls.
Compared with the CC genotype, carriers of IL-1B-511 TT genotype had an increased gastric cancer risk (odds ratio (OR)=1.97, 95% confidence interval (CI)=1.29-3.01, P=0.0016). TT genotype was significantly associated with intestinal type of gastric cancer (OR=3.16, 95% CI=1.74-5.71, P=0.0001) but not with diffuse or mixed-type gastric cancer. The test for OR heterogeneity between the intestinal-type and non-intestinal-type gastric cancers was statistically significant (P=0.02). In subgroup analyses, TT genotype was found to be associated with poorly differentiated gastric cancer (OR=3.31, 95% CI=1.43-3.60, P<0.0001), but not with moderately or well-differentiated gastric cancer. IL-1B-511 genotypes were not associated with the prognosis of gastric cancer patients.
IL-1B polymorphism influences certain subtypes of gastric cancer according to the clinical and pathological features. Understanding the etiologic heterogeneity of gastric cancer may result in improvements in controlling this disorder.
白细胞介素-1B（IL-1B）-511 多态性与胃癌的相关性仍存在争议，IL-1B-511 多态性与胃癌亚型的相关性在很大程度上仍不清楚。我们研究了 IL-1B-511 多态性与胃癌风险之间的关联是否因临床上重要的肿瘤特征而异，并在中国的一项大型基于人群的病例对照研究中评估了这种多态性的预后价值。
本研究于 1999 年至 2006 年在中国广东省进行，共纳入 1010 例胃癌患者和 1500 例健康对照者。采用聚合酶链反应-限制性片段长度多态性分析方法，在 501 例胃癌患者和 500 例健康对照者中检测 IL-1B-511 多态性。
与 CC 基因型相比，IL-1B-511 TT 基因型携带者胃癌风险增加（比值比（OR）=1.97，95%置信区间（CI）=1.29-3.01，P=0.0016）。TT 基因型与肠型胃癌显著相关（OR=3.16，95%CI=1.74-5.71，P=0.0001），但与弥漫型或混合型胃癌无关。肠型和非肠型胃癌之间的 OR 异质性检验具有统计学意义（P=0.02）。亚组分析显示，TT 基因型与低分化胃癌相关（OR=3.31，95%CI=1.43-3.60，P<0.0001），但与中分化或高分化胃癌无关。IL-1B-511 基因型与胃癌患者的预后无关。
IL-1B 多态性根据临床和病理特征影响某些胃癌亚型。了解胃癌的病因异质性可能有助于控制这种疾病。
